Acquisition of Surgical Biologics, LLC (Details) (USD $)	1 Months Ended	6 Months Ended
	Apr. 30, 2012	Jun. 30, 2012		Dec. 31, 2011
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life (in years)		14 years	[1]
Supplier Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life (in years)		14 years	[1]
Patents and know-how [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life (in years)		14 years	[1]
Licenses and permits [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life (in years)		3 years	[1]
Surgical Biologics [Member]
Business Acquisition [Line Items]
Cash Paid		$ 500,000
Convertible Promissory Notes, number of shares issuable (in shares)		1,250,000
Convertible Promissory Notes, interest rate (in hundredths)		4.00%
Common Stock issued (in shares)	2,632,576	5,250,000
Common Stock valued	3,185,223
Common stock held in escrow (in shares)		525,000
Terms Of Conversion Feature		The 4% Convertible Promissory Notes are convertible into up to 1,250,000 shares of the Company's common stock at $1.00 per share (a) at any time upon the election of the holder of the Convertible Notes; or (b) at the election of the Company, at any such time as the closing price per share of the Company's common stock (as reported by the OTCBB or on any national securities exchange on which the Company's shares may be listed, as the case may be) closes at no less than $1.75 per share for not less than 20 consecutive trading days in any period prior to the maturity date. If converted, the Common Stock will be available to be sold following satisfaction of the applicable conditions as set forth in Rule 144. The 4% Convertible Promissory Notes mature in eighteen (18) months and earn interest at 4% per annum on the outstanding principal amount payable in cash on the maturity date or convertible into shares of common stock of the Company as provided for above.
Convertible Promissory Note, conversion price (in dollars per share)		$ 1
Convertible Promissory Note, stock price trigger (in dollars per share)		$ 1.75
Beneficial Conversion Feature Recognized		437,500
Convertible Promissory Notes, unamortized discount		437,500
Actual purchase price allocated [Abstract]
Value of 5,250,000 shares issued at $1.35 per share		7,087,500
Cash paid at closing		350,000
Cash retained for working capital		150,000
Assumed Debt		182,777
Convertible Secured Promissory Note		1,250,000
Fair value of earn-out		7,404,700		7,410,503
Total fair value of purchase price		16,424,977
Common Stock, share price (in dollars per share)		1.35
Tangible assets:
Debt-free working capital		671,880
Other assets, net		385
Property, plant and equipment		72,866
Tangible assets purchased		745,131
Acquired Indefinite-lived Intangible Assets [Line Items]
Total acquired intangible assets		12,497,000
Goodwill		3,182,846
Total Assets Purchased		16,424,977
Working capital [Abstract]
Cash		33,583
Prepaid Expenses		2,738
Accounts Receivable		181,087
License Receivable		340,000
Inventory		347,106
Accounts payable and accrued expenses		(196,101)
Deferred rent and customer deposits		(36,533)
Debt-free working capital		671,880
Current portion of debt		(62,590)
Long-term debt		(21,187)
Line of credit		(99,000)
Net working capital		489,103
Deposits		16,582
Deferred rent (non-current)		(16,197)
Other assets, net		385
Surgical Biologics [Member] | Trade names and trademarks [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Acquired intangible asset		1,008,000
Surgical Biologics [Member] | In-process research and development - liquid [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Acquired intangible asset		2,160,000
Surgical Biologics [Member] | In-process research and development - other [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Acquired intangible asset		25,000
Surgical Biologics [Member] | Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired intangible assets		3,520,000
Weighted average useful life (in years)		14 years
Surgical Biologics [Member] | Supplier Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired intangible assets		241,000
Weighted average useful life (in years)		14 years
Surgical Biologics [Member] | Patents and know-how [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired intangible assets		5,530,000
Weighted average useful life (in years)		14 years
Surgical Biologics [Member] | Licenses and permits [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired intangible assets		$ 13,000
Weighted average useful life (in years)		3 years

[1] On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for customer and supplier relationships, patents and know-how, licenses/permits, trade names and trademarks and in-process research and development.